TLDR
- Novo Nordisk stock fell as much as 9% Monday after the drugmaker unveiled its strategy and long-term targets through 2030.
- Novo expects annual revenue growth from 2026 to 2030 to broadly match a group of large pharmaceutical peers.
- The company plans to launch more than five drugs with multi-blockbuster sales potential by 2030.
- Novo targets more than DKK 150 billion, or about $23 billion, in risk-adjusted pipeline sales by 2035.
- CEO Mike Doustdar said Novo plans to become more diversified as key semaglutide patents begin expiring early next decade.
Novo Nordisk (NVO) stock fell sharply Monday as investors responded to the drugmaker’s new long-term strategy. Copenhagen-listed stock dropped as much as 9% during the session after the company presented its 2030 targets in London.
The reaction came as Novo said it expects compound annual revenue growth between 2026 and 2030 to be broadly in line with pharmaceutical industry peers. Its adjusted operating margin is expected to remain broadly stable.
Those targets are strategic ambitions rather than formal financial guidance. Novo said the figures use 2026 as their starting point and remain subject to uncertainty.
The company is looking beyond the rapid growth delivered by Wegovy and Ozempic in recent years. CEO Mike Doustdar acknowledged that the approaching loss of patent protection for semaglutide is a central issue for investors.
Novo Targets Five New Blockbuster Drugs
Novo aims to launch more than five medicines with multi-blockbuster potential by 2030. It also expects its risk-adjusted pipeline to produce more than DKK 150 billion, or roughly $23 billion, in sales by 2035.
The company plans to have at least five Phase 3 programs in obesity and diabetes. Another five or more are planned across other therapeutic areas.
Novo also wants to reach more than 60 million patients worldwide by 2030. Manufacturing capacity for oral obesity medicines is expected to expand enough to serve around 15 million patients.
The company is broadening its pipeline beyond obesity and diabetes. Areas identified for further investment include cardiovascular disease, liver disease, blood disorders and endocrine conditions.
Doustdar said Novo intends to emerge from semaglutide’s loss of exclusivity as a larger and more diversified company. U.S. patent protection for semaglutide is expected to expire in 2032.
Investors Look for Faster Growth
The market reaction suggests investors had expected more aggressive financial targets. Novo’s plan to grow broadly in line with large pharmaceutical peers represents a slower pace than investors became accustomed to during Wegovy’s rapid expansion.
Novo entered Monday already under pressure. Before the session, its U.S.-listed stock had fallen roughly 27% over the previous 12 months, while rival Eli Lilly had gained ground.
Competition with Lilly remains central to Novo’s obesity strategy. Lilly’s Zepbound has taken market share in injectable treatments, while the companies are also competing in oral weight-loss medicines.
Novo did receive fresh clinical data Monday. CagriSema produced average weight loss of 12.4% in a late-stage diabetes study compared with 9.1% for a lower dose of Lilly’s tirzepatide.
The company plans a staged rollout of next-generation obesity treatments beginning with CagriSema in early 2027, followed by further products through 2028 and beyond.
Novo’s latest 2030 plan therefore combines pipeline expansion, greater oral GLP-1 capacity and diversification beyond obesity. The company said Monday that its long-term ambition remains to serve more than 60 million patients globally by 2030.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
